- Home
- KRYS
KRYS
Krystal Biotech Inc.
as 03-25-2025 4:00pm EST
Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | PITTSBURGH |
| Market Cap: | 5.2B | IPO Year: | 2017 |
| Target Price: | $220.00 | AVG Volume (30 days): | 266.2K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 3.00 | EPS Growth: | 669.23 |
| 52 Week Low/High: | $141.72 - $219.34 | Next Earning Date: | 05-05-2025 |
| Revenue: | $290,515,000 | Revenue Growth: | 473.02% |
| Revenue Growth (this year): | 60.34% | Revenue Growth (next year): | 47.35% |
Stock Insider Trading Activity of Krystal Biotech Inc. (KRYS)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Krishnan Krish S | KRYS | President and CEO | Mar 13 '25 | Sell | $177.74 | 50,000 | $8,889,524.59 | 1,556,956 | |
| Krishnan Suma | KRYS | President, R&D | Mar 13 '25 | Sell | $177.74 | 50,000 | $8,889,524.59 | 1,533,056 | |
| Romano Kathryn | KRYS | Chief Accounting Officer | Feb 26 '25 | Sell | $175.22 | 750 | $131,415.00 | 12,604 |
Latest Krystal Biotech Inc. News
KRYS Breaking Stock News: Dive into KRYS Ticker-Specific Updates for Smart Investing
Simply Wall St.
4 days ago
3 High Growth Companies Insiders Are Betting On
Zacks
4 days ago
Krystal Biotech (KRYS) Up 3.3% Since Last Earnings Report: Can It Continue?
Zacks
8 days ago
Here's Why Krystal Biotech, Inc. (KRYS) is a Strong Momentum Stock
MT Newswires
12 days ago
Krystal Biotech Insider Sold Shares Worth $8,889,525, According to a Recent SEC Filing
Zacks
18 days ago
Krystal Biotech Rises 15.8% in a Month: Should You Buy Now or Wait?
MT Newswires
20 days ago
Jefferies Initiates Krystal Biotech at Buy With $245 Price Target
Argus Research
21 days ago
KRYS: Lowering target price to $184.00
Zacks
22 days ago
KRYS Gets Positive CHMP Opinion for EU Approval of Skin Disease Drug
Compare KRYS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "KRYS Krystal Biotech Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.